Registration for a live webinar on 'Innovations in antibiotic discovery: combating resistant infections' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Introduction
-
1. Editor's foreword
- Prof. Ann Daly
-
2. Introduction to drug metabolism enzymes
- Dr. Dennis Smith
- General factors affecting drug metabolism
-
3. General factors affecting drug metabolism: effect of physiological factors and disease 1
- Prof. Edward T. Morgan
-
4. General factors affecting drug metabolism: effect of physiological factors and disease 2
- Prof. Edward T. Morgan
-
5. Drug metabolism in liver disease
- Dr. Nathalie Zgheib
- Prof. Robert Branch
-
7. Prediction of pathways of drug metabolism
- Dr. Maurice Dickins
- Phase I metabolizing enzymes: cytochrome P450s
-
8. Cytochrome P450 1 family: the roles of 1A1, 1A2 and 1B1 in drug metabolism
- Prof. F. Peter Guengerich
-
9. CYP2 family
- Prof. Ann Daly
-
10. Why study the cytochrome P4503A (CYP3A) family?
- Dr. Erin Schuetz
-
11. Pharmacogenomics: an update
- Prof. Magnus Ingelman-Sundberg
- Phase I metabolizing enzymes: non-cytochrome P450s
-
12. Non-P450 oxidative metabolism: characteristics and drug substrates
- Dr. Christine Beedham
-
13. UDP-glucuronosyltransferases
- Prof. Abby Collier
- Phase II metabolizing enzymes: conjugating enzymes
-
14. Glutathione transferases
- Prof. Ralf Morgenstern
-
15. Arylamine N-acetyltransferases 1
- Prof. Edith Sim
-
16. Arylamine N-acetyltransferases 2
- Prof. Edith Sim
-
17. Arylamine N-acetyltransferases 3
- Prof. Edith Sim
-
18. Methyltransferases
- Prof. Richard Weinshilboum
-
19. Amino acid conjugation: mechanism and enzymology
- Dr. Kathleen Knights
- Clinical aspects
-
20. Clinical significance of enzyme induction and inhibition
- Prof. Kim Brøsen
-
21. Clinical importance of pharmacogenetic polymorphisms affecting drug metabolism
- Prof. Julia Stingl (formerly Kirchheiner)
- Latest Updates in the Field
-
22. Mammalian flavin-containing monooxygenases
- Prof. Allan Rettie
- Archived Lectures *These may not cover the latest advances in the field
-
23. Glucuronidation and the UDP - glucuronosyltransferases
- Prof. Peter Mackenzie
- Prof. John Miners
-
25. Catalytic cycle of cytochrome P450s
- Prof. Gordon Roberts
-
26. Drug metabolism and liver disease
- Prof. Robert Branch
-
27. Crystal structures of drug-metabolizing P450 monooxygenases
- Prof. Eric Johnson
-
28. Sulfation and human cytosolic sulfotransferases
- Prof. Charles Falany
-
29. Laboratory methods for the in vitro study of drug metabolism
- Dr. Charles Crespi
-
30. Clinical importance of pharmacogenetic polymorphisms affecting drug metabolism: psychopharmacology and pain
- Prof. Julia Stingl (formerly Kirchheiner)
-
32. Pharmacogenomics
- Prof. Magnus Ingelman-Sundberg
Printable Handouts
Navigable Slide Index
- Introduction
- DMEs in inflammation and infection
- Inflammation
- Detoxification of pentobarbital sodium (Nembutal)
- Hepatic cytochrome P-450-dependent systems
- Theophylline pharmacokinetics during infection
- LPS model of inflammation & bacterial sepsis
- DME gene expression and LPS in rat/mouse liver
- Endotoxin inhibits P450-mediated drug metabolism
- Regulation of P450s in inflammation/infection
- Infectious/inflammatory stimuli & drug metabolism
- LPS vs. local inflammatory reaction
- In vivo role of cytokines: knockout mice (1)
- In vivo role of cytokines: knockout mice (2)
- Transcriptional & post-transcriptional mechanisms
- Mechanisms of transcriptional downregulation
- Inducible vs. constitutive expression suppression
- P450 & NO activity in inflammation
- Role of physiological NO in CYP suppression
- Infectious/inflammatory stimuli & drugs (humans)
- Inflammation & CYP3A4 in cancer patients
- Disease-dependent drug-drug interaction
- Thanks
Topics Covered
- Effect of physiological and pathophysiological conditions on drug-metabolizing enzymes (DMEs)
- Role of growth hormones and transcription factors in sex-dependent expression
- Drug clearance and age
- Developmental regulation
- Impact of infection and inflammatory disease on DME expression
- Clinical consequences
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Morgan, E.T. (2017, July 31). General factors affecting drug metabolism: effect of physiological factors and disease 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved May 13, 2025, from https://doi.org/10.69645/WCOR3227.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Edward T. Morgan, Grants/Research Support (Principle Investigator): One research grant from the National Institutes of Health
General factors affecting drug metabolism: effect of physiological factors and disease 2
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:03
We will now move on to the topic of drug metabolism in inflammatory disease states which,
as we will see, is applicable to a wide variety of diseases in humans.
0:16
The symptoms of inflammation were described more than two centuries ago by Celsus,
tumor, rubor, calor and dolour,
or, swelling, redness, heat and pain.
These symptoms are the result of
a local or systemic response to infection or injury designed to
eliminate or control invading pathogens or to
allow tissue recovery and repair following injury.
But an exaggerated, inappropriate or chronic inflammatory response
can be deleterious and many human diseases have an inflammatory component.
Local inflammation is characterized by vasodilation,
neutrophil recruitment and a cascade of
pro-inflammatory cytokine and they cause node release.
The triggering events of an inflammatory response are many and varied.
But, in the case of infection usually result from the activation by microbial products of
pattern recognition receptors such as
Toll-like receptors on cells of the innate or adaptive immune systems.
Physical or thermally-derived injuries initiate inflammation by activating
mast cells in the tissues which release histamine and tumor necrosis factor alpha,
again initiating the inflammatory cascade.
1:30
Perhaps, the first indication that inflammation could affect
drug metabolism was this publication from 1953 by Samaras and Dietz.
Analogous to the experiments we discussed earlier,
these investigators were studying the metabolism of pentobarbital in
rats by measuring the time the animals slept after a single dose of the barbiturate.
They injected the animals with trypan blue,
an activator of the immune system or saline.
They then injected pentobarbital and measured the sleeping time.
Animals treated with trypan blue slept longer than the control animals
indicating that the metabolism clearance of pentobarbital had been impaired.
Only sporadic additional contributions to
Hide